BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33753907)

  • 21. Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysis.
    Dill V; Blüm P; Lindemann A; Biederstädt A; Högner M; Götze KS; Bassermann F; Hildebrandt M
    Transfusion; 2024 May; 64(5):871-880. PubMed ID: 38600674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
    Milone G; Martino M; Spadaro A; Leotta S; Di Marco A; Scalzulli P; Cupri A; Di Martina V; Schinocca E; Spina E; Tripepi G
    Br J Haematol; 2014 Jan; 164(1):113-23. PubMed ID: 24138497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
    Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):34-40. PubMed ID: 30149148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
    Tichopád A; Vítová V; Kořístek Z; Lysák D
    J Clin Apher; 2013 Dec; 28(6):395-403. PubMed ID: 23922227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
    Awan F; Kochuparambil ST; Falconer DE; Cumpston A; Leadmon S; Watkins K; Deremer D; Jillella A; Craig M; Hamadani M
    Bone Marrow Transplant; 2013 Oct; 48(10):1279-84. PubMed ID: 23584435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
    Zannetti BA; Saraceni F; Cellini C; Fabbri E; Monaco F; Guarini A; Laszlo D; Martino M; Olivieri A; Imola M; Tosi P; Chiarucci M; Zuffa E; Lanza F
    Transplant Cell Ther; 2021 Mar; 27(3):244.e1-244.e8. PubMed ID: 33781522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.
    Milone G; Martino M; Leotta S; Spadaro A; Zammit V; Cupri A; Avola G; Camuglia MG; Di Marco A; Scalzulli P; Morelli M; Olivieri A; Tripepi G
    Leuk Lymphoma; 2018 Jan; 59(1):42-48. PubMed ID: 28573902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a reduced dose of plerixafor in combination with granulocyte colony-stimulating factor in healthy haploidentical stem cell donors.
    Kurnikova E; Trakhtman P; Balashov D; Garloeva J; Kumukova I; Khismatullina R; Pershin D; Shelikhova L; Novichkova G; Maschan A
    Vox Sang; 2022 Jun; 117(6):853-861. PubMed ID: 35332550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization].
    Duan WB; Dou XL; Lei L; Wang FR; Huang XJ; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):21-26. PubMed ID: 33677864
    [No Abstract]   [Full Text] [Related]  

  • 31. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.
    Antar A; Otrock ZK; Kharfan-Dabaja MA; Ghaddara HA; Kreidieh N; Mahfouz R; Bazarbachi A
    Bone Marrow Transplant; 2015 Jun; 50(6):813-7. PubMed ID: 25751646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK
    Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
    Karres D; Ali S; van Hennik PB; Straus S; Josephson F; Thole G; Glerum PJ; Herberts C; Babae N; Herold R; Papadouli I; Pignatti F
    Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor.
    Morris C; Chabannon C; Masszi T; Russell N; Nahi H; Kobbe G; Krejci M; Auner HW; Pohlreich D; Hayden P; Basak GW; Lenhoff S; Schaap N; van Biezen A; Knol C; Iacobelli S; Liu Q; Celanovic M; Garderet L; Kröger N
    Bone Marrow Transplant; 2020 Feb; 55(2):356-366. PubMed ID: 31534192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
    Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
    Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
    Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
    Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
    Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
    J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.
    Ri M; Matsue K; Sunami K; Shimazaki C; Hayashi A; Sunaga Y; Sasaki T; Suzuki K
    Int J Hematol; 2017 Oct; 106(4):562-572. PubMed ID: 28527129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of mobilization regimen on multiday collection of peripheral blood CD34+ cells by large volume leukapheresis.
    Siddiqui I; Shmookler A; Biller E; Hardy T; Hartage R; Losos M; Chen J
    Transfusion; 2022 Apr; 62(4):857-862. PubMed ID: 35211978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.